Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9320685 | 0.95 | ZDHHC20 (0.43) | RAD52KDM4EZDHHC20ZDHHC2CYP1A2 | |
| SCHEMBL83920 | 0.86 | RAD52 (0.44) | RAD52KDM4ECYP1A2ALDH1A1MAPT | |
| SCHEMBL9321561 | 0.85 | ZDHHC20 (0.42) | KDM4EZDHHC20ZDHHC2CYP1A2ALDH1A1 | |
| SCHEMBL9176002 | 0.80 | BRD4 (0.36) | TSHR | |
| Urea SCHEMBL27513933 | 0.79 | TSHR (0.46) | ALDH1A1TSHRTGM2KMT2A | |
| SCHEMBL27790589 | 0.78 | ZDHHC20 (0.58) | KDM4EZDHHC20ZDHHC2ALDH1A1TSHR | |
| SCHEMBL21611 | 0.78 | ZDHHC20 (0.58) | KDM4EZDHHC20ZDHHC2ALDH1A1TSHR | |
| SCHEMBL9126544 | 0.78 | TSHR (0.35) | ALDH1A1TSHRTGM2KMT2A | |
| SCHEMBL27680447 | 0.77 | TSHR (0.43) | ZDHHC20ZDHHC2ALDH1A1TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL131505 | 0.77 | ZDHHC20 (0.56) | KDM4EZDHHC20ZDHHC2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059917-A1 | MODIFIED RELEASE DOSAGE FORM COMPRISING DESVENLAFAXINE OR SALTS THEREOF | JAIN GIRISH KUMAR (IN) | 2013-03-07 | — | — | US | claimed |
| EP-2552419-A2 | MODIFIED RELEASE DOSAGE FORM COMPRISING DESVENLAFAXINE OR SALTS THEREOF | Wockhardt Limited (IN) | 2013-02-06 | — | — | EP | claimed |
| WO-2011121475-A2 | MODIFIED RELEASE DOSAGE FORM COMPRISING DESVENLAFAXINE OR SALTS THEREOF | WOCKHARDT LIMITED (IN) | 2011-10-06 | — | — | WO | claimed |
| US-20100234288-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A pH-DEPENDENT POLYMER | PANACEA BIOTEC LTD (IN) | 2010-09-16 | — | — | US | claimed |
| US-20100056493-A1 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITION AND A PROCESS OF MAKING THE SAME | PANACEA BIOTEC LIMITED (IN) | 2010-03-04 | — | — | US | claimed |
| EP-2114380-A1 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITION AND A PROCESS OF MAKING THE SAME | Panacea Biotec Ltd. (IN) | 2009-11-11 | — | — | EP | claimed |
| WO-2009118763-A1 | MULTILAYERED PHARMACEUTICAL COMPOSITIONS AND PROCESSES THEREOF | PANACEA BIOTEC LIMITED (IN) | 2009-10-01 | — | — | WO | claimed |
| US-20090099154-A1 | Pharmaceutical Sustained Release Compositions and Processes Thereof | PANACEA BIOTEC LTD. (IN) | 2009-04-16 | — | — | US | claimed |
| EP-2004150-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF A RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A PH-DEPENDENT POLYMER. | Panacea Biotec Ltd. (IN) | 2008-12-24 | — | — | EP | claimed |
| WO-2008122993-A1 | CONTROLLED RELEASE FORMULATION OF COATED MICROPARTICLES | PANACEA BIOTEC LIMITED (IN) | 2008-10-16 | — | — | WO | claimed |
| US-6828293-B1 | Suitable catalysts for oxidations with peroxy compounds, especially within the context of washing procedures | CIBA SPECIALTY CHEMICALS CORPORATION | 2004-12-07 | — | — | US | claimed |
| US-6825162-B2 | PARTICLES COMPRISING A SALDIMINE-TYPE MANGANESE COMPLEX AND AT LEAST 10% BY WEIGHT OF A POLYMERIC DISSOLUTION RESTRAINER PROVIDE BETTER INHIBITION OF THE REDEPOSITION OF MIGRATING DYES IN WASHING LIQUORS THAN BY PURE MANGANESE COMPLEX | CIBA SPECIALTY CHEMICALS CORPORATION | 2004-11-30 | — | — | US | claimed |
| EP-0959123-B1 | Water soluble granulate of phthalocyanine compounds | CIBA SC HOLDING AG (CH) | 2004-07-28 | — | — | EP | claimed |
| US-20040142842-A1 | Process for the preparation of water-soluble granules or particles of saldimine-type manganese complexes | CIBA SPECIALTY CHEMICALS CORP. | 2004-07-22 | — | — | US | claimed |
| WO-2004022693-A1 | FORMULATIONS COMPRISING WATER-SOLUBLE GRANULATES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-03-18 | — | — | WO | claimed |
| EP-1354025-A1 | PROCESS FOR THE PREPARATION OF WATER-SOLUBLE GRANULES OR PARTICLES OF SALDIMINE-TYPE MANGANESE COMPLEXES | Ciba SC Holding AG (CH) | 2003-10-22 | — | — | EP | claimed |
| WO-2002059245-A1 | PROCESS FOR THE PREPARATION OF WATER-SOLUBLE GRANULES OR PARTICLES OF SALDIMINE-TYPE MANGANESE COMPLEXES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-08-01 | — | — | WO | claimed |
| EP-1200545-A1 | WATER-SOLUBLE GRANULES OF SALEN-TYPE MANGANESE COMPLEXES | Ciba SC Holding AG (CH) | 2002-05-02 | — | — | EP | claimed |
| US-6291412-B1 | ADDITIVES TO WASHING AGENTS FOR TEXTILE MATERIALS. ANIONIC DISPERSING AGENT, | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-09-18 | — | — | US | claimed |
| WO-2001009276-A1 | WATER-SOLUBLE GRANULES OF SALEN-TYPE MANGANESE COMPLEXES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-02-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059917-A1 | MODIFIED RELEASE DOSAGE FORM COMPRISING DESVENLAFAXINE OR SALTS THEREOF | CYP2D6, SLC6A4, SLC6A2 | RAD52 3760/4885KDM4E 1493/4885ZDHHC20 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.